STEVENSON, M . d .., May 13, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that the class action lawsuit has been commenced in the usa District Court for a Southern District of New York on behalf of purchasers of Ventrus Biosciences, Inc. ("Ventrus" or the "Company") (Nasdaq: VTUS) common stock in the period between December seventeen, 2010 and June 31, 2012, inclusive (the "Class Period").
Should you have suffered a net loss from investment in Ventrus Biosciences, Inc. common stock purchased on or simply after December 17, 2010, and held through June twenty-five, 2012, you may obtain additional information about this lawsuit and your ability to become lead plaintiff by getting in contact with Brower Piven at online world. browerpiven. com, by e-mail at hoffman@browerpiven. com, as a result of calling 410/415-6616, or with Brower Piven, A Professional Corporation, 1925 Old Pit Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have got combined experience litigating securities and class action cases of over 60 years.
No class has yet been certified in the above action. Members for the Class will be represented from the lead plaintiff and counsel chosen from the lead plaintiff. If you need to choose counsel to represent you and the Class, you must connect with be appointed lead plaintiff zero later than July 8, 2013 and grow selected by the Court. The lead plaintiff might direct the litigation and play important decisions including whether to simply accept a settlement and what amount of of a settlement in order to for the Class inside the action. The lead plaintiff can be selected from among applicants claiming the largest loss from investment inside Company during the Category Period.
The complaint accuses your defendants of violations in the Securities Exchange Act with 1934 by virtue for the defendants falsely representing over the Class Period that their lead product iferanserin (VEN 309) ("VEN 309"), for the topical treatment of symptomatic internal hemorrhoids, was an unusual product that had simply no competing products approved by way of the U. S. Food and Drug Administration ("FDA"), that VEN 309 would be the first and only product or service specifically approved for use being a prescription treatment for hemorrhoids, that the prior stage II and IIB reviews of VEN 309 constantly demonstrated reduction of hemorrhoidal conditions, that the Company can leverage VEN 309 to your market of over 12. 5 thousand thousand potential patients, and of the fact that Phase III clinical litigation for VEN 309 was "low risk" relative to most therapeutic drug advancement programs. According to this complaint, following the Firm's June 25, 2012 disclosure that VEN 309 were unable its Phase III trial prior to the FDA and that this company would abandon further improvement of VEN 309, including deeper attempt to obtain FDA acceptance, the value of Ventrus stock shares declined significantly.
If you choosed retain counsel, you may retain Brower Piven without the need of financial obligation or cost to you, or you may retain other counsel with the choice. You need take no action at this time to be a person in the class.
No comments:
Post a Comment